What is the Dishman Carbogen Amcis Ltd share price today?

The share price of NSE:DCAL-EQ on 01 Oct 2026 (as of 15:03:22 IST) is ₹149.88.

What is the NSE:DCAL-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:DCAL-EQ 52 week high low range shows a high of ₹306 and a low of ₹128.5.

What is the Dishman Carbogen Amcis Ltd market cap?

As on 01 Oct 2026, Dishman Carbogen Amcis Ltd market cap is ₹24607100000.

What is the shareholding pattern of Dishman Carbogen Amcis Ltd Stock?

The shareholding pattern of Dishman Carbogen Amcis Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 59.32% Foreign Institutional Investors (FII): 6.86% Domestic Institutional Investors (DII): 0.64% Mutual Funds: 1.41% Retail & Others: 31.77% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Dishman Carbogen Amcis Ltd?

The Price-to-Earnings (PE) ratio of Dishman Carbogen Amcis Ltd is 152.272, and the Price-to-Book (PB) ratio is 0.3053, as on 01 Oct 2026.

Dishman Carbogen Amcis Share Price

148.26-1.42 (-0.95%)

-49.55% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-0.95%

1 Week

-2.75%

1 Month

-11.35%

3 Month

-23.95%

6 Month

-11.10%

YTD

-40.12%

1 Year

-49.55%

5 Year

-38.23%

10 Year

Max

-57.64%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

147.75

145.37

128.50

High

150.46

153.25

177.57

202.85

224.40

303.00

About

Dishman Carbogen Amcis Limited (DCAL), incorporated in 1983, started out as a manufacturer of quaternary ammonium and phosphate compounds. Currently, the company is a fully integrated CRAMS player working with Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

LAURUSLABSNSE

CIPLANSE

MANKINDNSE

DRREDDYNSE

AUROPHARMANSE

LUPINNSE

DCALNSE

LTP

1W Low

1W High

Market cap (₹)

1621.8-159.2 (-8.94%)

1621.80

1936

4,20,483Cr

9329-259 (-2.70%)

8557

9916

2,49,248Cr

4634.9-81.3 (-1.72%)

4198.50

4795

1,77,822Cr

1084-69 (-5.98%)

1050

1229.20

1,11,242Cr

2018.9-33.9 (-1.65%)

1833

2150

1,08,062Cr

1305.2-22 (-1.66%)

1170.90

1431.10

1,05,427Cr

2368.2-131.8 (-5.27%)

2297.40

2539.30

99,065Cr

1193.9-9.9 (-0.82%)

1077.30

1316.70

98,492Cr

1652-30 (-1.78%)

1592

1777.70

94,477Cr

1957.7-55.2 (-2.74%)

1796.50

2152.10

88,806Cr

147.96-4.5 (-2.95%)

145.37

155.89

2,301Cr

Dishman Carbogen Amcis Share Price

148.26-1.42 (-0.95%)

-49.55% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years9%

3 years7%

Last year8%

Compounded Profit Growth

10 years-

5 years-

3 years-

Last year2908%

Stock Price CAGR

10 years-

5 years-9%

3 years-2%

1 year-49%

Return on Equity

10 years366%

5 years0%

3 years0%

Last year2%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	9%	7%	8%
-	-	-	2908%
-	-9%	-2%	-49%
366%	0%	0%	2%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

LAURUSLABS

CIPLA

DRREDDY

MANKIND

AUROPHARMA

LUPIN

DCAL

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,751.4	₹421539 Cr	34.85	12.07	62.82	₹11479 Cr
9,378.5	₹247576 Cr	84.64	34.04	128.41	₹2568 Cr
4,624.7	₹177251 Cr	81.27	16.72	97.06	₹2163 Cr
1,113.1	₹111232 Cr	24.65	9.42	62.53	₹5040 Cr
2,038.9	₹109797 Cr	100.42	6.8	29.25	₹889 Cr
1,302.1	₹105290 Cr	31.24	9.77	57.87	₹3879 Cr
1,226.6	₹99753 Cr	30.96	5.32	63.99	₹4196 Cr
2,401.3	₹97850 Cr	47.9	13.75	71.08	₹1913 Cr
1,690	₹97015 Cr	26.13	17.95	96.84	₹3505 Cr
1,942.3	₹89629 Cr	16.21	30.95	154.35	₹5333 Cr
148.26	₹2341 Cr	144.85	-3.69	23.23	₹97 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020	Mar 2020	Dec 2019	Sep 2019	Jun 2019	Mar 2019	Dec 2018	Sep 2018	Jun 2018	Mar 2018	Dec 2017	Sep 2017	Jun 2017	Mar 2017	Dec 2016	Sep 2016
₹678 Cr	₹851 Cr	₹720 Cr	₹653 Cr	₹708 Cr	₹716 Cr	₹682 Cr	₹789 Cr	₹524 Cr	₹655 Cr	₹651 Cr	₹587 Cr	₹723 Cr	₹619 Cr	₹640 Cr	₹614 Cr	₹541 Cr	₹569 Cr	₹562 Cr	₹459 Cr	₹551 Cr	₹529 Cr	₹469 Cr	₹439 Cr	₹474 Cr	₹512 Cr	₹542 Cr	₹467 Cr	₹522 Cr	₹650 Cr	₹479 Cr	₹448 Cr	₹482 Cr	₹451 Cr	₹460 Cr	₹444 Cr	₹340 Cr	₹534 Cr	₹362 Cr	₹434 Cr
₹18 Cr	₹16 Cr	₹7 Cr	₹8 Cr	₹25 Cr	₹8 Cr	₹6 Cr	₹7 Cr	₹1 Cr	₹7 Cr	₹6 Cr	₹8 Cr	₹7 Cr	₹7 Cr	₹7 Cr	₹9 Cr	₹6 Cr	₹4 Cr	₹19 Cr	₹10 Cr	₹10 Cr	₹6 Cr	₹9 Cr	₹15 Cr	₹9 Cr	₹21 Cr	₹9 Cr	₹7 Cr	₹8 Cr	₹20 Cr	₹13 Cr	₹15 Cr	₹6 Cr	₹16 Cr	₹15 Cr	₹9 Cr	₹7 Cr	₹4 Cr	₹16 Cr	₹13 Cr
₹696 Cr	₹868 Cr	₹726 Cr	₹661 Cr	₹733 Cr	₹724 Cr	₹688 Cr	₹796 Cr	₹525 Cr	₹662 Cr	₹657 Cr	₹595 Cr	₹730 Cr	₹625 Cr	₹646 Cr	₹623 Cr	₹546 Cr	₹573 Cr	₹581 Cr	₹469 Cr	₹561 Cr	₹535 Cr	₹478 Cr	₹454 Cr	₹483 Cr	₹533 Cr	₹551 Cr	₹474 Cr	₹530 Cr	₹670 Cr	₹492 Cr	₹463 Cr	₹488 Cr	₹467 Cr	₹474 Cr	₹453 Cr	₹346 Cr	₹538 Cr	₹378 Cr	₹446 Cr
₹708 Cr	₹777 Cr	₹691 Cr	₹588 Cr	₹649 Cr	₹643 Cr	₹614 Cr	₹714 Cr	₹565 Cr	₹677 Cr	₹690 Cr	₹601 Cr	₹672 Cr	₹643 Cr	₹576 Cr	₹615 Cr	₹527 Cr	₹631 Cr	₹528 Cr	₹434 Cr	₹525 Cr	₹518 Cr	₹485 Cr	₹438 Cr	₹505 Cr	₹479 Cr	₹489 Cr	₹392 Cr	₹470 Cr	₹551 Cr	₹404 Cr	₹377 Cr	₹416 Cr	₹381 Cr	₹394 Cr	₹365 Cr	₹321 Cr	₹445 Cr	₹314 Cr	₹376 Cr
₹78 Cr	₹179 Cr	₹120 Cr	₹157 Cr	₹165 Cr	₹161 Cr	₹146 Cr	₹154 Cr	₹30 Cr	₹70 Cr	₹47 Cr	₹69 Cr	₹128 Cr	₹58 Cr	₹120 Cr	₹87 Cr	₹94 Cr	₹26 Cr	₹129 Cr	₹109 Cr	₹111 Cr	₹94 Cr	₹72 Cr	₹95 Cr	₹52 Cr	₹128 Cr	₹134 Cr	₹152 Cr	₹127 Cr	₹189 Cr	₹146 Cr	₹144 Cr	₹127 Cr	₹137 Cr	₹136 Cr	₹142 Cr	₹77 Cr	₹151 Cr	₹115 Cr	₹125 Cr
₹37 Cr	₹43 Cr	₹46 Cr	₹42 Cr	₹43 Cr	₹42 Cr	₹49 Cr	₹37 Cr	₹32 Cr	₹31 Cr	₹33 Cr	₹27 Cr	₹28 Cr	₹24 Cr	₹22 Cr	₹20 Cr	₹19 Cr	₹16 Cr	₹15 Cr	₹14 Cr	₹12 Cr	₹9 Cr	₹14 Cr	₹13 Cr	₹12 Cr	₹20 Cr	₹11 Cr	₹17 Cr	₹14 Cr	₹13 Cr	₹14 Cr	₹15 Cr	₹15 Cr	₹11 Cr	₹13 Cr	₹13 Cr	₹11 Cr	₹10 Cr	₹13 Cr	₹20 Cr
-₹51 Cr	₹46 Cr	-₹10 Cr	₹31 Cr	₹39 Cr	₹28 Cr	₹27 Cr	₹42 Cr	-₹78 Cr	-₹49 Cr	-₹66 Cr	-₹36 Cr	₹29 Cr	-₹88 Cr	₹46 Cr	-₹12 Cr	-₹30 L	-₹85 Cr	₹38 Cr	₹19 Cr	₹24 Cr	-₹14 Cr	-₹22 Cr	₹4 Cr	-₹34 Cr	₹35 Cr	₹51 Cr	₹65 Cr	₹46 Cr	₹106 Cr	₹74 Cr	₹71 Cr	₹58 Cr	₹75 Cr	₹68 Cr	₹74 Cr	₹14 Cr	₹83 Cr	₹50 Cr	₹51 Cr
-₹58 Cr	₹22 Cr	-₹13 Cr	₹65 Cr	₹23 Cr	₹43 Cr	₹5 Cr	₹33 Cr	-₹78 Cr	-₹70 Cr	-₹60 Cr	-₹41 Cr	₹17 Cr	-₹71 Cr	₹47 Cr	-₹10 Cr	₹4 Cr	-₹45 Cr	₹35 Cr	₹11 Cr	₹16 Cr	-₹135 Cr	-₹16 Cr	₹7 Cr	-₹21 Cr	₹50 Cr	₹33 Cr	₹41 Cr	₹34 Cr	₹76 Cr	₹51 Cr	₹44 Cr	₹40 Cr	₹51 Cr	₹42 Cr	₹48 Cr	₹13 Cr	₹43 Cr	₹33 Cr	₹38 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Secured Loans

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
—	—	—	—	—	—	—	—	—	—
₹31 Cr	₹31 Cr	₹31 Cr	₹31 Cr	₹31 Cr	₹31 Cr	₹31 Cr	₹32 Cr	₹32 Cr	₹0
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹4810 Cr
₹6646 Cr	₹5800 Cr	₹5596 Cr	₹5778 Cr	₹5518 Cr	₹5667 Cr	₹5684 Cr	₹5347 Cr	₹5075 Cr	₹4 Cr
₹6646 Cr	₹5800 Cr	₹5596 Cr	₹5778 Cr	₹5518 Cr	₹5667 Cr	₹5684 Cr	₹5347 Cr	₹5075 Cr	₹4 Cr
₹6677 Cr	₹5832 Cr	₹5628 Cr	₹5810 Cr	₹5549 Cr	₹5699 Cr	₹5715 Cr	₹5379 Cr	₹5107 Cr	₹4814 Cr
₹1535 Cr	₹1129 Cr	₹246 Cr	₹1047 Cr	₹762 Cr	₹504 Cr	₹222 Cr	₹311 Cr	₹386 Cr	₹241 Cr
₹0	₹20 Cr	₹0	₹0	₹0	₹0	₹19 Cr	₹52 Cr	₹139 Cr	₹219 Cr
-₹71 Cr	-₹56 L	₹29 Cr	₹61 Cr	₹125 Cr	₹182 Cr	₹138 Cr	₹132 Cr	₹125 Cr	₹80 Cr
₹955 Cr	₹729 Cr	₹735 Cr	₹491 Cr	₹501 Cr	₹370 Cr	₹236 Cr	₹0	₹0	₹5 Cr
₹428 Cr	₹352 Cr	₹379 Cr	₹233 Cr	₹277 Cr	₹311 Cr	₹294 Cr	₹248 Cr	₹234 Cr	₹221 Cr
₹2846 Cr	₹2230 Cr	₹1388 Cr	₹1831 Cr	₹1665 Cr	₹1367 Cr	₹909 Cr	₹743 Cr	₹884 Cr	₹767 Cr
—	—	—	—	—	—	—	—	—	—
₹211 Cr	₹231 Cr	₹244 Cr	₹220 Cr	₹193 Cr	₹169 Cr	₹284 Cr	₹195 Cr	₹186 Cr	₹86 Cr
₹1166 Cr	₹993 Cr	₹640 Cr	₹842 Cr	₹702 Cr	₹559 Cr	₹579 Cr	₹430 Cr	₹516 Cr	₹457 Cr
₹837 Cr	₹655 Cr	₹1620 Cr	₹681 Cr	₹493 Cr	₹542 Cr	₹688 Cr	₹520 Cr	₹393 Cr	₹385 Cr
₹103 Cr	₹46 Cr	₹51 Cr	₹56 Cr	₹31 Cr	₹20 Cr	₹18 Cr	₹53 Cr	₹83 Cr	₹66 Cr
₹2317 Cr	₹1925 Cr	₹2555 Cr	₹1798 Cr	₹1420 Cr	₹1290 Cr	₹1569 Cr	₹1198 Cr	₹1178 Cr	₹994 Cr
₹11840 Cr	₹9986 Cr	₹9571 Cr	₹9439 Cr	₹8634 Cr	₹8356 Cr	₹8193 Cr	₹7321 Cr	₹7169 Cr	₹6574 Cr
₹429 Cr	₹423 Cr	₹427 Cr	₹443 Cr	₹415 Cr	₹394 Cr	₹404 Cr	₹355 Cr	₹241 Cr	₹222 Cr
₹2775 Cr	₹2084 Cr	₹1964 Cr	₹1825 Cr	₹1421 Cr	₹1166 Cr	₹1056 Cr	₹1042 Cr	₹1095 Cr	₹950 Cr
—	—	—	—	—	—	—	—	—	—
₹12412 Cr	₹10545 Cr	₹10309 Cr	₹9458 Cr	₹8633 Cr	₹8155 Cr	₹7891 Cr	₹6897 Cr	₹6621 Cr	₹6187 Cr
₹4341 Cr	₹3495 Cr	₹3588 Cr	₹3275 Cr	₹2865 Cr	₹2462 Cr	₹2218 Cr	₹1805 Cr	₹1560 Cr	₹1340 Cr
₹8071 Cr	₹7051 Cr	₹6720 Cr	₹6183 Cr	₹5768 Cr	₹5693 Cr	₹5673 Cr	₹5092 Cr	₹5061 Cr	₹4847 Cr
₹275 Cr	₹252 Cr	₹501 Cr	₹996 Cr	₹755 Cr	₹425 Cr	₹202 Cr	₹143 Cr	₹119 Cr	₹122 Cr
₹75 Cr	₹72 Cr	₹79 Cr	₹72 Cr	₹32 Cr	₹56 Cr	₹84 Cr	₹147 Cr	₹101 Cr	₹40 Cr
₹75 Cr	₹72 Cr	₹79 Cr	₹72 Cr	₹32 Cr	₹56 Cr	₹84 Cr	₹147 Cr	₹101 Cr	₹40 Cr
₹275 Cr	₹190 Cr	₹193 Cr	₹217 Cr	₹211 Cr	₹412 Cr	₹413 Cr	₹345 Cr	₹299 Cr	₹201 Cr
₹2 Cr	₹2 Cr	₹66 L	₹81 L	₹66 L	₹35 L	₹5 Cr	₹1 Cr	₹6 Cr	₹16 Cr
₹8998 Cr	₹7786 Cr	₹7642 Cr	₹7521 Cr	₹6795 Cr	₹6652 Cr	₹6414 Cr	₹5767 Cr	₹5623 Cr	₹5241 Cr
—	—	—	—	—	—	—	—	—	—
₹16 Cr	₹25 Cr	₹23 Cr	₹177 Cr	₹293 Cr	₹116 Cr	₹107 Cr	₹20 Cr	₹94 Cr	₹0
₹1019 Cr	₹900 Cr	₹883 Cr	₹804 Cr	₹645 Cr	₹516 Cr	₹581 Cr	₹549 Cr	₹485 Cr	₹427 Cr
₹673 Cr	₹665 Cr	₹484 Cr	₹590 Cr	₹473 Cr	₹421 Cr	₹577 Cr	₹445 Cr	₹444 Cr	₹286 Cr
₹991 Cr	₹507 Cr	₹413 Cr	₹189 Cr	₹172 Cr	₹308 Cr	₹161 Cr	₹96 Cr	₹69 Cr	₹87 Cr
₹32 Cr	₹22 Cr	₹45 Cr	₹38 Cr	₹66 Cr	₹146 Cr	₹76 Cr	₹135 Cr	₹81 Cr	₹172 Cr
₹110 Cr	₹80 Cr	₹79 Cr	₹121 Cr	₹189 Cr	₹198 Cr	₹277 Cr	₹309 Cr	₹373 Cr	₹361 Cr
₹2842 Cr	₹2200 Cr	₹1928 Cr	₹1918 Cr	₹1839 Cr	₹1704 Cr	₹1779 Cr	₹1554 Cr	₹1546 Cr	₹1333 Cr
₹525 Cr	₹276 Cr	-₹627 Cr	₹120 Cr	₹419 Cr	₹414 Cr	₹210 Cr	₹355 Cr	₹368 Cr	₹339 Cr
₹11840 Cr	₹9986 Cr	₹9571 Cr	₹9439 Cr	₹8634 Cr	₹8356 Cr	₹8193 Cr	₹7321 Cr	₹7169 Cr	₹6574 Cr
₹426	₹372	₹359	₹371	₹354	₹363	₹364	₹333	₹316	₹0
₹426	₹372	₹359	₹371	₹354	₹363	₹364	₹333	₹316	₹0

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
₹105 Cr	₹19 Cr	-₹122 Cr	-₹55 Cr	-₹4 Cr	-₹65 Cr	₹197 Cr	₹309 Cr	₹231 Cr	₹216 Cr
₹436 Cr	₹467 Cr	₹377 Cr	₹392 Cr	₹325 Cr	₹313 Cr	₹330 Cr	₹277 Cr	₹235 Cr	₹232 Cr
-₹45 Cr	-₹85 Cr	₹144 Cr	-₹38 Cr	₹90 Cr	₹316 Cr	₹132 Cr	-₹174 Cr	-₹206 Cr	-₹29 Cr
₹496 Cr	₹402 Cr	₹398 Cr	₹300 Cr	₹411 Cr	₹564 Cr	₹660 Cr	₹412 Cr	₹260 Cr	₹418 Cr
₹491 Cr	₹371 Cr	₹379 Cr	₹266 Cr	₹355 Cr	₹513 Cr	₹585 Cr	₹282 Cr	₹226 Cr	₹303 Cr
-₹245 Cr	-₹192 Cr	-₹230 Cr	-₹494 Cr	-₹619 Cr	-₹380 Cr	-₹442 Cr	-₹169 Cr	-₹297 Cr	-₹142 Cr
₹201 Cr	-₹102 Cr	-₹22 Cr	₹250 Cr	₹130 Cr	-₹11 Cr	-₹98 Cr	-₹102 Cr	₹78 Cr	-₹137 Cr
₹447 Cr	₹77 Cr	₹128 Cr	₹22 Cr	-₹133 Cr	₹122 Cr	₹46 Cr	₹11 Cr	₹7 Cr	₹23 Cr
₹341 Cr	₹264 Cr	₹132 Cr	₹110 Cr	₹244 Cr	₹122 Cr	₹76 Cr	₹66 Cr	₹59 Cr	₹0
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹35 Cr
₹0	₹0	₹5 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹65 L
₹788 Cr	₹341 Cr	₹264 Cr	₹132 Cr	₹110 Cr	₹244 Cr	₹122 Cr	₹76 Cr	₹66 Cr	₹59 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Dishman Carbogen Amcis Share Price

148.26-1.42 (-0.95%)

-49.55% past 1 Year

Shareholding summary

Promoters

59.32%

FII

6.86%

DII

0.64%

1.41%

Others

31.77%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
59.32%	59.32%	59.32%	59.32%	59.32%	59.32%
6.86%	7.45%	7.66%	8.07%	9.94%	9.49%
0.64%	0.56%	0.18%	0.28%	0.19%	0.19%
1.41%	1.06%	1.08%	1.08%	1.07%	1.06%
31.77%	31.61%	31.76%	31.25%	29.48%	29.94%

Bulk & block deals

Name

Crony Vyapar Pvt Ltd

Graviton Research Capital Llp

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
11 Dec 2024	Purchase	33.38 Cr	₹299.19	11.16 L	Bulk	0.711572	NSE
11 Dec 2024	Sell	34.05 Cr	₹299.90	11.35 L	Bulk	0.724208	NSE
09 Dec 2024	Purchase	37.01 Cr	₹277.86	13.32 L	Bulk	0.849494	NSE
09 Dec 2024	Sell	31.59 Cr	₹277.82	11.37 L	Bulk	0.725189	NSE
05 Mar 2024	Purchase	24.05 Cr	₹276.33	8.70 L	Bulk	0.555206	NSE
05 Mar 2024	Sell	23.70 Cr	₹276.77	8.56 L	Bulk	0.546276	NSE
04 Mar 2024	Purchase	27.44 Cr	₹267.80	10.25 L	Bulk	0.653453	NSE
04 Mar 2024	Sell	23.28 Cr	₹268.49	8.67 L	Bulk	0.553055	NSE
28 Dec 2023	Purchase	16.02 Cr	₹173.12	9.25 L	Bulk	0.590287	NSE
28 Dec 2023	Sell	16.02 Cr	₹173.06	9.25 L	Bulk	0.590287	NSE

Insider trading & SAST

Client name

Aditi J Vyas & Mansi J Vyas

Param Value Investments

Nikunj Desai

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
08 May 2024	Promoter	Acquisition	11.86	—	0	—	1.86 Cr	01 Jan 1900	—	—	SAST	10(5)	—
13 Jul 2023	Other	Acquisition	0.96	5.23	0	—	15 L	20 Jun 2023	Market	82,00,000	SAST	29(1)	—
16 Feb 2023	Immediate Relative	Acquisition	0.000353	0.01	55.34 K	₹99.90	554	15 Feb 2023	Market Purchase	13,500	Insider Trading	—	Equity Shares
16 Feb 2023	Immediate Relative	Acquisition	0.003654	0.01	5.71 L	₹99.75	5.73 K	13 Feb 2023	Market Purchase	12,946	Insider Trading	—	Equity Shares

Dishman Carbogen Amcis Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Dishman Carbogen Amcis Share Price

Dishman Carbogen Amcis Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Dishman Carbogen Amcis Share Price

Dishman Carbogen Amcis Share Price

Oscillators

Moving averages

Dishman Carbogen Amcis Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Dishman Carbogen Amcis Share Price

Corporate Actions

Company details

Dishman Carbogen Amcis Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Dishman Carbogen Amcis Share Price

News

Dishman Carbogen subsidiary clears first US FDA audit at Swiss plant

Dishman Carbogen Amcis subsidiary clears first US FDA inspection, no observations

Dishman Carbogen Q4 EBITDA rises YoY but margin contracts on lower profitability

Dishman Carbogen Q4 revenue grows strongly year-on-year to Rs 851 crores

Dishman Carbogen reports lower quarterly net profit in latest result

Dishman Carbogen Amcis Subsidiary Carbogen Amcis B.V. Secures GMP Compliance Certificate for Veenendaal Facility.

Dishman Carbogen Amcis Q3 FY26 EBITDA Decline: YoY Margin Contraction

Dishman Carbogen Amcis Reports Q3 Net Loss of Rs 13 Crores vs YoY Profit.

Dishman Carbogen Amcis board clears Rs 50 crores secured NCD issue at 10 percent

Dishman Carbogen Amcis Board Meeting on Dec 27 to Discuss NCD Funding Proposal.

Dishman Carbogen Amcis subsidiary secures expanded Swiss credit capacity through refinancing initiative.

Dishman Carbogen Amcis Q2 FY26: Net profit rises sharply as revenue falls; operating margin expands

Dishman Carbogen Amcis merges Carbogen Amcis Specialities AG and Carbogen Amcis Innovations AG

Dishman Carbogen Amcis announces partnership with Celonic Group for ADC platform development

Dishman Carbogen Amcis rises on receiving EIR from USFDA

Dishman Carbogen Amcis receives EIR from USFDA

Dishman Carbogen Amcis: Company Gets Eir From Us Fda Confirming Inspection Closure. ??

Dishman Carbogen Amcis: Co Is Expanding Complex Api Capabilities, Deepening Cdmo Partnerships, And Leveraging Regulatory Clearances In The U.S. & Eu To Tap High-Value Pharma Outsourcing Demand

Dishman Carbogen Amcis: Q1 Ebitda 140.00 Crores Rupees Vs 30.00 Crores (Yoy) || Q1 Ebitda Margin 19.82% Vs 5.73% (Yoy)

Dishman Carbogen Amcis: Q1 Cons Net Profit 23.40 Crores Rupees Vs Loss 77.60 Crores (Yoy) || Q1 Revenue 708.00 Crores Rupees Vs 523.00 Crores (Yoy)

Dishman Carbogen Amcis Ltd Share Price Today

Dishman Carbogen Amcis Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator